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Mutations in HPCA Cause Autosomal-Recessive
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Reports of primary isolated dystonia inherited in an autosomal-recessive (AR) manner, often lumped together as ‘‘DYT2 dystonia,’’ have
appeared in the scientific literature for several decades, but no genetic cause has been identified to date. Using a combination of homo-
zygosity mapping and whole-exome sequencing in a consanguineous kindred affected by AR isolated dystonia, we identified homozy-
gous mutations in HPCA, a gene encoding a neuronal calcium sensor protein found almost exclusively in the brain and at particularly
high levels in the striatum, as the cause of disease in this family. Subsequently, compound-heterozygous mutations in HPCA were also
identified in a second independent kindred affected by AR isolated dystonia. Functional studies suggest that hippocalcin might play a
role in regulating voltage-dependent calcium channels. The identification of mutations in HPCA as a cause of AR primary isolated dys-
tonia paves the way for further studies to assess whether ‘‘DYT2 dystonia’’ is a genetically homogeneous condition or not.Dystonia is a common movement disorder characterized
by twisting or repetitive movements with or without
tremor.1 Dystonia occurring with no other neurological
signs on clinical examination and normal neuroimaging
is currently classified as ‘‘primary isolated dystonia.’’ Men-
delian forms of this primary isolated dystonia have been
associated with several genes (TOR1A [MIM 605204],2
THAP1 [MIM 609250],3 CIZ1 [MIM 611420],4 ANO3
[MIM 610110],5 GNAL [MIM 139312],6 and TUBB4A
[MIM 602662]7,8), all of which are inherited in an auto-
somal-dominant fashion. Previous reports have nonethe-
less suggested that an autosomal-recessive (AR) form of
primary isolated dystonia might exist. In general, these
reports have been lumped together under the banner of
DYT2 (MIM 224500) or ‘‘DYT2-like’’ dystonia.9–12 DYT2
is thus somewhat of an anomaly given that it is defined
purely by phenotype and presumed mode of inheritance
without any associated linkage interval. The sole exception
to this practice was the creation in 2008 of the DYT17 locus
to designate a chromosome 20 region, defined by homozy-
gosity mapping, in a consanguineous Lebanese kindred
exhibiting isolated AR dystonia.13 Yet, as with DYT2, the
genetic cause remains to be identified.13
With the advent of next-generation sequencing technol-
ogies, we revisited a Sephardic Jewish kindred exhibiting
AR isolated dystonia that had previously been classified
as ‘‘DYT2-like.’’10 The three affected siblings (now aged
61, 57, and 51 years) were the product of a consanguineous
marriage between two first cousins. Both parents were
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The Amtonia within the wider kindred (Figure 1A and extended
pedigree in Khan et al.10). In brief, in their first decade of
life, all three affected siblings developed dystonia, which
gradually generalized over time but remainedmost marked
in the upper limbs and cervical and cranial regions.
Initially, the siblings were reported to have an atypical
form of metachromatic leukodystrophy (MLD) on the ba-
sis of markedly reduced levels of arylsulfatase A in fibro-
blasts and leucocytes, reduced nerve conduction velocities,
and the detection of brown metachromatic granules in
sural nerve biopsies. Subsequent mutational screening by
Sanger sequencing demonstrated that the mother and
the three siblings were homozygous and that the father
was heterozygous for two variants in a cis configuration,
c.[1055A>G; *96A>G] (RefSeq accession number
NM_000487.5), which are commonly referred to collec-
tively as the ‘‘polyA mutation,’’ in the gene ARSA (MIM
607574). The polyA mutation results in reduced amounts
of arylsulfatase A on biochemical assay and has no clinical
symptoms (a state termed pseudodeficiency). No other
mutations were detected in the remainder of the gene at
that time or in the current study. In this context, the detec-
tion of metachromatic granules in the sural nerve biopsy is
unusual. Nonetheless, despite prolonged follow-up, no
clinical or radiological features of progressive central or
peripheral demyelination have developed, making MLD
highly unlikely. On current examination, there are no
other neurological features besides the dystonia detectable
on clinical examination, and exhaustive radiological and
biochemical investigations have failed to reveal anyquare, London WC1N 3BG, UK; 2Department of Medical and Molecular Ge-
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Figure 1. Genetic Pedigrees for Families Affected by Mutations
in HPCA
Abbreviated genetic pedigrees are shown for the core members of
(A) the index family and (B) the second family identified to be
affected by compound-heterozygous mutations in HPCA. For the
family in (B), the results of the segregation analysis are shown
under each individual: WT, wild-type allele; M1, c.212C>A
(p.Thr71Asn) mutation; M2, c.568G>C (Ala190Thr) mutation.
The results are consistent with AR inheritance of dystonia due to
biallelic mutations in HPCA. Individual II:6 did not report any
symptoms suggestive of dystonia; however, this could not be
confirmed by examination because he did not live in the UK.underlying cause. Extensive genetic testing—including but
not confined to TOR1A, THAP1, GNAL, and ANO3—has
not revealed a causal mutation in these genes. Although
the severity of the dystonia has gradually increased over
time, the clinical course appears relatively benign: all three
of the affected siblings continue to function well in daily
life, there is no significant limitation of ambulation, and
fixed deformities have not developed. This study was
approved by the relevant local ethics committee at our
institution, and informed consent was provided by all
participants in accordance with its guidelines.
DNA was extracted from whole-blood samples obtained
from all three affected siblings and both parents. DNA
from one affected sibling was used for performing whole-
exome sequencing with Illumina’s TruSeq (62 Mb) DNA
sample preparation and exome enrichment kits. With the
TruSeq exome definition as a reference, coverage was 96%
at a read depth of 23, 87% at a read depth of 103, and
74% at a read depth of 203. The mean read depth across
the exomewas 583. In total, 22,097 variantswere detected.
Genome-wide genotyping data were generated with the
OmniExpress platform (~500,000 markers) and used for
performing homozygosity mapping. Tracts of potential
homozygosity greater than 1 Mb were initially identified
for each individual. The boundaries of overlapping homo-
zygosity tracts shared by all three affected individuals
were subsequently determined. Coverage across regions of
shared homozygosity was calculated with BedTools against
the Consensus Coding Sequence (CCDS) definition of the658 The American Journal of Human Genetics 96, 657–665, April 2, 2exome and was expressed as the percentage of target bases
covered by at least one read (see Table 1). Mean coverage
of CCDS genes across all homozygous regions was 90.7%.
In view of the apparently recessive inheritance pattern
and history of consanguinity, we initially selected all
homozygous variants for consideration. Subsequently,
synonymous variants not predicted to affect splicing
(i.e., those not within ten bases, in either direction, of
the intron-exon boundary) were discarded. Given the
rarity of AR isolated dystonia, we further hypothesized
that the causal variant would not be found in any database
of normal sequence variation. However, in order to mini-
mize the possibility of incorrectly assigning causality, we
filtered out only those variants at a minor allele frequency
of greater than 0.5%. Given that a variant found at even
this frequency would be expected to occur naturally in
the homozygous state in around 1 in every 160,000 births,
it seemed distinctly unlikely that we would risk filtering
out the causal variant with this cutoff. Finally, variants
that were located in regions of shared homozygosity were
selected as potentially causal (see Table 1). No filtration
was performed on the basis of in silico predictions of
pathogenicity or conservation scores.
Filtering of the exome data as above left just two
possible candidate causal homozygous variants (both
located in the largest stretch of shared homozygosity
on chromosome 1) for further consideration: the first
(c.625G>A [p.Val209Met]; RefSeq NM_006762.2) was in
exon 7 of LAPTM5 (MIM 601476), which encodes a lyso-
somal transmembrane protein, and the second (c.225C>A
[p.Asn75Lys]; RefSeq NM_002143.2) was in exon 2 of
HPCA (MIM 142622), which encodes the neuronal cal-
cium sensor (NCS) protein known as hippocalcin.
To aid in determining which was the most plausible
candidate, we obtained (1) in silico predictions of patho-
genicity from SIFT, PROVEAN, PolyPhen-2, and Muta-
tionTaster and (2) expression data for each gene, and we
assessed the location of the detected variants in relation
to predicted protein functional domains (see Table 2 and
Figure 2). Although the variants in both genes showed
high levels of conservation and were universally predicted
to be damaging, the variant in HPCA appeared to be the
stronger candidate because (1) the variant affected a key
functional domain of the protein and (2) the gene is almost
exclusively expressed in the brain—particularly in the
striatum, an area connected to movement disorders—
whereas LAPTM5 is expressed poorly in the brain and
most avidly in tissues involved in hemopoiesis.
In fact, the p.Asn75Lys variant in hippocalcin affects an
amino acid that is known to be critical to a key functional
domain’s calcium-binding properties. All NCS proteins,
including hippocalcin, are characterized by four EF-hand
domains that act as potential Ca2þ binding sites. However,
EF-hand domain 1 is invariably inactive in binding
divalent cations, and EF-hand domain 4 is only active in
some NCS proteins. Canonical Ca2þ-binding EF-hand
domains are characterized by the semi-conserved sequence015
Table 1. Regions of Homozygosity and Exome Sequencing
Chr Start End Length (Mb) CCDS Genes Coverage
Variants
Detected
Potentially
Causal Variants
1 12,880,356 20,476,391 7.60 86 84.3% 166 0
1 26,909,765 34,686,130 7.78 102 91.0% 43 2
3 126,380,804 127,502,549 1.12 7 97.9% 5 0
5 98,552,184 99,968,045 1.42 1 100% 0 0
6 34,502,022 36,226,525 1.72 28 95.9% 16 0
7 64,926,823 66,464,764 1.54 10 82.7% 3 0
8 48,639,976 49,656,604 1.02 5 80.5% 3 0
8 85,802,488 86,990,451 1.19 8 89.7% 4 0
11 47,976,882 51,591,253 3.61 13 95.9% 32 0
11 54,794,237 55,943,322 1.15 25 89.4% 52 0
For each homozygous region shared between all three siblings, the table shows genomic coordinates (UCSC Genome Browser hg19), the length (Mb), the num-
ber of CCDS genes that lie in the region, the percentage of CCDS bases (including UTRs) covered by exome sequencing, the number of variants detected in that
region, and the number of potentially causal variants that remained after filtration, as detailed in the methods. The following abbreviation is used: Chr, chromo-
some.motif D-X-D/N-X-D/N-G-(X)5-E, where the underlined
obligate amino acids are involved in the coordinative bind-
ing of Ca2þ.15,16 The p.Asn75Lys variant in hippocalcin
results in a substitution of the second Ca2þ-coordinating
residue of the binding sequence within EF-hand domain
2. Usually, only one of two amino acids will be found at
this position: a negatively charged aspartic acid or a neutral
asparagine (as in wild-type hippocalcin). Unsurprisingly,
the amino acid at this position shows absolute interspecies
conservation (Figure S1A). Moreover, the p.Asn75Lys
variant leads to the incorporation of a positively charged
lysine, which might reasonably be expected to cause a
particular impediment to the binding of the similarly
charged Ca2þ ion.
In wild-type NCS proteins, binding of Ca2þ to their func-
tional EF-hand domains operates a myristoyl switch mech-
anism—most extensively studied in the related neural
protein recoverin—that controls the protein’s ability to
translocate to target membranes and/or interact with
downstream effectors (Figure S2).17–19 By means of this
mechanism, NCS proteins, like hippocalcin, are able to
act as reversible transducers of cellular Ca2þ signals and
are thus capable of integrating both temporal and spatial
aspects over a tight dynamic range.17 Thus, it is plausible
to hypothesize that the homozygous p.Asn75Lys variant,
by impairing or even preventing Ca2þ binding to EF-
hand domain 2, would be expected to reduce the likeli-
hood of conformational change of hippocalcin in response
to Ca2þ signals and, by extension, result in a defect in
cellular Ca2þ signal transduction in the striatum, an area
of the brain intimately connected with movement disor-
ders, such as dystonia.
Despite the greater inherent biological plausibility of
the variant in HPCA, we next attempted to find further
confirmatory mutations in either candidate gene. To doThe Amso, we obtained dystonia samples (donated with research
consent) from a DNA bank held at our institution. Despite
the extensive nature of this clinical resource, the rarity of
AR isolated dystonia meant that there were no other sam-
ples available from any other dystonia kindred in whom
the inheritance pattern could definitively be said to be
AR. We were therefore forced instead to select subjects for
whom the history was merely ‘‘not incompatible’’ with
AR inheritance (i.e., subjects with either no family history
or a family history of affected siblings only). All subjects
had been screened previously for mutations in TOR1A,
and no mutations had been identified.
In order to reduce consumption of DNA and protect
this valuable clinical resource for future use, we adopted
a two-phased screening strategy. In the first phase, we
aimed to identify the most likely candidate genes by
sequencing only the exons in which the potentially causal
variants were identified in the index family in an indepen-
dent cohort of 150 subjects with young-onset (<30 years
of age), non-autosomal-dominant dystonia of any distri-
bution (younger age of onset was prioritized). In addition,
we included a DNA sample from an affected member of
the DYT17 kindred. We did not detect any further poten-
tially causal variants in exon 7 of LAPTM5. In exon 2 of
HPCA, however, we detected a second, heterozygous,
missense variant (c.212C>A) resulting in an amino acid
substitution (p.Thr71Asn) at a position just 4 amino acids
before the location of the original homozygous variant
found in the index family. The affected nucleotide
shows extremely high conservation scores (PhyloP ¼
5.76 [max ¼ 6]; PhastCons ¼ 1 [max ¼ 1]), and the
affected amino acid is conserved in all species. Although
this amino acid is not recognized as an obligatory Ca2þ
coordinator itself, it is still within the second EF-hand
domain of hippocalcin (amino acids 60–95 according toerican Journal of Human Genetics 96, 657–665, April 2, 2015 659
Table 2. Candidate Causal Variants after Filtration
Homozygous Change
c.625G>A
(p.Val209Met)
c.225C>A
(p.Asn75Lys)
Chromosome 1 1
Position (hg19) 31,208,094 33,354,724
Gene
(RefSeq transcript)
LAPTM5
(NM_006762.2)
HPCA
(NM_002143.2)
Previously reported no no
PhyloP C (3.37) C (2.71)
PhastCons C (1) C (1)
SIFT D (0.001) D (0.001)
PROVEAN D (2.7) D (5.239)
PolyPhen-2 D (0.999) D (0.993)
MutationTaster D (0.986) D (0.999)
Functional domain
of protein
no yes: EF-hand
domain 2
A summary of both candidate causal variants includes conservation scores
(PhyloP and PhastCons), in silico predictions of pathogenicity (SIFT, PROVEAN,
PolyPhen-2, and MutationTaster), and the location of the variant with respect
to predicted functional domains of the protein (from UniProt). ‘‘Previously
reported’’ refers to the whether the variant can be found in dbSNP, the NHLBI
Exome Sequencing Project Exome Variant Server, 1000 Genomes, and Com-
plete Genomics 69. Both variants are conserved and predicted to be damaging
by all four prediction programs. Actual numerical scores provided by the
in silico prediction programs are shown here in parentheses for the sake of
completeness, and readers are referred to the programs’ websites for a detailed
explanation of their meaning. Abbreviations are as follows: C, conserved;
and D, damaging.UniProt) and is predicted to be damaging, with near
maximal probability scores, by all four in silico prediction
programs.
On the basis of this finding, in the second phase, we
went on to sequence all coding exons of HPCA in the
same 151 samples and also in a second cohort of 288
non-autosomal-dominant, young-onset (<40 years of
age) subjects exhibiting dystonia that was either general-
ized or most prominent in the upper limbs or cervical or
cranial region (i.e., we prioritized a distribution similar to
the phenotype observed in other families). We found
only one additional variant of any kind, and this was in
the same sample that harbored the p.Thr71Asn substi-
tution. The additional variant was a missense mutation
(c.568G>C [p.Ala190Thr]) located toward the end of
HPCA exon 4, which encodes the C terminus of the pro-
tein. The nucleotide involved is conserved (PhyloP ¼
2.015; PhastCons ¼ 1), and the affected amino acid is con-
served in most species, except the fly (D. melanogaster) and
the Tasmanian devil (S. harrisii). However, only Muta-
tionTaster predicts it to be disease causing; SIFT, PROVEAN,
and PolyPhen-2 predict that the substitution will be
tolerated. The p.Ala190Thr substitution is not located in
any EF-hand domain, and the mechanism by which it
might impair protein function is less obvious. However,
we note that it has previously been suggested that the660 The American Journal of Human Genetics 96, 657–665, April 2, 2C-terminal regions of other NCS proteins might be
involved in fine-tuning their response or determining
target specificity.20,21
We established contact with the individual whose DNA
sample harbored the compound-heterozygous mutations
in HPCA—a 64 year-old woman of Sri Lankan origin—to
verify the medical and family history and perform a full
neurological examination. She reported that the onset of
dystonia was in her early twenties, possibly even her late
teens. It initially manifested with abnormal involuntary
fingermovements thatweremostnoticeablewhen she tried
to type. Over time, her dystonia very gradually worsened: a
tremulous component emerged, but the dystonia remained
segmental, such that it affected only the hands, arms,
and muscles of the neck, and would be classified clinically
as mild. Despite the fact that she is one of seven siblings,
no other family member, including her parents, siblings,
and her siblings’ children, reported or were reported to
have any symptoms consistent with dystonia, and this
was confirmed by clinical examination where possible
(Figure 1B). Segregation analysis in the four surviving
siblings demonstrated that the remaining unaffected
siblings possessed either one or both wild-type alleles
(Figure 1B), supporting the pathogenicity of the com-
pound-heterozygous mutations in the affected individual.
It is notable that, with the exception of the single sample
detailed above, we did not detect any other coding or
splice-site variant—previously annotated or not— in
HPCA in any of the other subjects screened. This low level
of variation is confirmed by the pooled next-generation
sequencing results of the NHLBI Exome Sequencing
Project, ClinSeq, 1000 Genomes, and the International
HapMap Project, which have collectively identified only
eight separate missense variants (none of which are homo-
zygous) in the 8,451 individuals of various ethnicities for
whom data have so far been made public (Table S1). By
way of comparison, on the basis of the same datasets, 31
missense (11 of which are predicted to be damaging by
both SIFT and PolyPhen-2), two splice-site, and one frame-
shift variant have been detected in LAPTM5. Although we
cannot, because of a lack of data, be certain that this low
level of variation in HPCA extends to all populations,
this observation does at least further increase the likeli-
hood that the identification of compound-heterozygous
HPCA mutations segregating perfectly with disease in a
second dystonia-affected kindred was very unlikely to
have occurred by chance.
Given the position and nature of the p.Asn75Lys and
p.Thr71Asn variants, we hypothesized that they would
lead to a loss of function. We therefore performed short
hairpin RNA (shRNA) knockdown of Hpca on rat primary
neurons and astrocytes and used the resultant cells to mea-
sure, by means of fura-2 florescence microscopy, the effect
of hippocalcin deficiency on cellular calcium homeostasis
after exposure to different neuropharmacological agents.
For primary cortical cultures, Wistar WT rat pups
were culled between postnatal days 1 and 3, and a primary015
Figure 2. Expression Data for LAPTM5 and HPCA
(A and B) Publically available expressed sequence tag (EST) data for (A) LAPTM5 and (B) HPCA demonstrate that both genes show
relatively tissue-specific expression patterns. LAPTM5 is predominantly expressed in hemopoietic tissues, whereasHPCA is almost exclu-
sively expressed in the brain.
(C) Boxplot ofmRNA expression levels forHPCA in ten CNS regions. Data are based on in-house exon array experiments and plotted on a
log2 scale (y axis). A full description of the samples used, the methods of RNA isolation and processing, and data-analysis steps can be
found in Trabzuni et al.14 This plot shows significant variation in HPCA transcript expression across the ten CNS regions analyzed:
putamen (PUTM, n ¼ 129), hippocampus (HIPP, n ¼ 122), temporal cortex (TCTX, n ¼ 119), frontal cortex (FCTX, n ¼ 127), occipital
cortex (OCTX, n ¼ 129), thalamus (THAL, n ¼ 124), cerebellar cortex (CRBL, n ¼ 130), substantia nigra (SNIG, n ¼ 101), intralobular
white matter (WHMT, n ¼ 131), and medulla (specifically inferior olivary nucleus, MEDU, n ¼ 109). HPCAmRNA expression is highest
in the putamen, followed closely by the hippocampus. Expression is also high in the cortex. Whiskers extend from the box to 1.53 the
inter-quartile range.co-culture was prepared as described elsewhere.22 Cerebral
hemispheres were trypsinized and resuspended in 2 ml of
warm complete Neurobasal A medium, and the cell sus-
pension was plated on poly-L-lysine-coated coverslips.
The cultures were incubated at 37C in a humidified incu-
bator with 5% CO2 in the air for 3–4 hr, and then 2 ml of
pre-warmed complete Neurobasal A medium was added.
Hpca knockdown in rat cortical primary cultures was per-
formed by Effectene transfection (QIAGEN) after 9–10 days
in culture with either a pool of four rat-specific shRNAs or
individual shRNAs targeting rat Hpca (Thermo Fischer).
The empty vector (pGIPZ) and the vector expressing a
non-targeting RNA (SCR) were used as controls. The trans-
fection was made according to the manufacturer’s instruc-
tions, and 48 hr after transfection, the cells were ready for
subsequent experiments.
We stimulated the resultant cells with (1) 5 mMglutamate
to simulate a physiological calcium signal in neurons viaThe Amactivation of glutamate receptors, (2) 100 mMATP to stimu-
late P2Y receptors in astrocytes, and (3) 50 mM potassium
chloride (KCl) to depolarize neuronal membranes and
induce the opening of voltage-gated calcium channels.
We found that application of glutamate resulted in
a smaller, but non-significant, neuronal response to gluta-
mate in Hpca-shRNA-transfected neurons (0.95 5 0.4,
n ¼ 35; see Figure 3A, lower panel) than in the controls
transfected with scrambled vector (1.35 5 0.4, n ¼ 35,
p ¼ 0.48) and empty vector (1.455 0.3, n ¼ 21, p ¼ 0.38;
see Figure 3B, upper panel).
Astrocytic signal to stimulation with 100 mM ATP in
Hpca-knockdown cells was also smaller (0.6 5 0.2, n ¼
55; Figures 3C and 3D) than that in control cells trans-
fected with scrambled vector (1.4 5 0.35, n ¼ 45) and
empty vector (0.9 5 0.5, n ¼ 28), but the reduction in
signal only reached significance when Hpca-knockdown
cells were compared to scrambled controls (p ¼ 0.04).erican Journal of Human Genetics 96, 657–665, April 2, 2015 661
Figure 3. Summary of the Functional Studies in Hpca-Knockdown Neuronal-Astrocytic Co-cultures
Astrocytes and neurons from primary cortical co-culture were loaded for 30 min at room temperature with 5 mM fura-2 AM and 0.005%
pluronic acid in a HEPES-buffered salt solution composed of 156 mM NaCl, 3 mM KCl, 2 mMMgSO4, 1.25 mM KH2PO4, 2 mM CaCl2,
10 mM glucose, and 10 mM HEPES (pH was adjusted to 7.35 with NaOH). Fluorescence measurements were obtained on an epifluores-
cence inverted microscope equipped with a 203 fluorite objective. [Ca2þ]c was monitored in single cells with excitation light provided
by a Xenon arc lamp, and the beam passed through a monochromator at 340 and 380 nm (Cairn Research). Emitted fluorescence light
was reflected through a 515-nm longpass filter to a charge-coupled-device camera (Retiga, QImaging) and digitized to a 12-bit resolution.
All imaging data were collected and analyzed with software from Andor IQ. The fura-2 data were not calibrated in terms of [Ca2þ]c
because of the uncertainty arising from the use of different calibration techniques. Areas for the analysis were chosen depending on
the GFP fluorescence intensity, and four independent experiments were performed for each condition. The figure shows representative
traces of [Ca2þ]c response to physiological stimuli as measured by changes in fura-2 fluorescence intensity. Compared to neurons
from the scrambled or empty control (A, black triangle trace), Hpca-knockdown neurons showed no rise in [Ca2þ]c in response to depo-
larization of the plasmamembrane with 50 mM KCl (A, dark-gray trace; B, dark-gray bars). In addition, the amplitude of the response to
physiological concentration of glutamate (5 mM) was lower in the Hpca-knockdown neurons than in control cells (B, black bars),
although this decrease was not statistically significant. Hpca knockdown also diminished the amplitude of the [Ca2þ]c response of astro-
cytes to an ATP stimulus (100 mM) (C and D, light-gray trace and bars). Error bars represent the SEM, and asterisks represents statistical
significance (***p < 0.0001, *p < 0.05).Somewhat unexpectedly, the most significant difference
between Hpca-silenced and control neurons was observed
after depolarization of the plasma membrane by appli-662 The American Journal of Human Genetics 96, 657–665, April 2, 2cation of 50 mM KCL. As anticipated, this resulted in a
strong Ca2þ signal in control neurons transfected with
scrambled vector (1.65 5 0.45, n ¼ 35) and empty vector015
(1.755 0.34, n¼ 21). InHpca-shRNA-transfected neurons,
however, application of KCL produced almost no observ-
able Ca2þ signal (0.15 0.02, n ¼ 35; p ¼ 0.001 versus con-
trols with scrambled vector, and p< 0.0001 versus controls
with empty vector; Figures 3A and 3B). Importantly, all of
these cells demonstrated a clear response to glutamate,
confirming their neuronal origin (Figure 3B).
Together, this pattern of severely altered neuronal re-
sponses to physiological stimuli suggests that HPCA
deficiency might inhibit voltage-dependent Ca2þ channels
or, alternatively, modify the mechanism of maintaining
the membrane potential and thus affect cellular response
to membrane depolarization.
In summary, we have presented evidence to support
biallelic mutations in HPCA as a cause of AR primary
isolated dystonia. This discovery resolves the mystery
surrounding the nature of DYT2 dystonia and decisively
settles the debates over the existence of an AR form of
isolated dystonia. Although we were only able to identify
one additional family affected by dystonia secondary to
mutations in HPCA, this is consistent with the relative
rarity of the disorder, and it is unlikely that any European
or American institution would have had a significantly
higher number of cases. However, screening of further suit-
able cases, particularly in geographical regions with higher
rates of consanguinity, will be needed to give a better idea
of its actual prevalence. This should be relatively easy given
the small size of the gene.
This identification of variants in hippocalcin, an NCS
protein detected in greatest abundance in the striatum,
as the cause of a Mendelian form of dystonia suggests a
role for perturbed calcium signaling in the pathogenesis
of this condition. In terms of future research, it is impor-
tant to note that NCS proteins, such as hippocalcin,
possess no inherent enzymatic properties but exert their
Ca2þ-dependent functions through interactions with
other proteins. Thus, the identification of downstream
interactors is a necessary first step in understanding their
specific activities. In the case of hippocalcin, the identity
of its interactors remains incomplete. There is, nonethe-
less, evidence to suggest that it might have a role in (1)
the modulation of cyclic nucleotide signaling in the
olfactory epithelium,23 (2) long-term depression in the
hippocampus,24–26 (3) generation of the slow afterhyper-
polarization current (important in controlling neuronal
excitability),27–29 (4) regulation of gene transcription,30,31
and (5) neurite outgrowth.32 Although some other,
currently unknown function of hippocalcin might under-
lie its involvement in dystonia, it is notable that, in rela-
tion to the processes mentioned above, both aberrant
excitability of striatal neurons and altered synaptic
plasticity due in part to decreased long-term depression
are two mechanisms believed to be important in at least
some forms of dystonia.33–36
Hippocalcin has been most intensely studied in relation
to its role in synaptic plasticity within the hippocampus,
where it is hypothesized to play a role in memory forma-The Amtion. Indeed, Hpca-knockout mice show deficits in tests
of spatial and associative memory in the absence of
any obvious structural abnormalities within the brain.30
Difficulties with memory were not, however, reported by
any of the individuals in whom we detected HPCA muta-
tions, and this study did not have ethical approval or
funding to perform detailed neuropsychological testing.
However, recent neuropsychological testing performed
with consent as part of the medical investigation of one
member of the index family did show evidence of cogni-
tive underfunctioning, including particular difficulties in
encoding verbal and visual information.Whether memory
deficits represent a subtle and variable associated pheno-
type in humans with HPCA mutations (as does hyposmia
in those with GNAL mutations37) or whether the neuro-
psychological deficits observed in the individual in this
study were an incidental finding remains an open question
that only the identification of further affected individuals
and a study dedicated to their neuropsychological profiling
will answer.Supplemental Data
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